Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 552644 | ISIN: US6289681099 | Ticker-Symbol:
1-Jahres-Chart
NASB FINANCIAL INC Chart 1 Jahr
5-Tage-Chart
NASB FINANCIAL INC 5-Tage-Chart
PR Newswire
161 Leser
Artikel bewerten:
(1)

NASB Financial, Inc. Announces Retirement of Chief Executive Officer

Finanznachrichten News

KANSAS CITY, Mo., Oct. 4, 2024 /PRNewswire/ -- NASB Financial, Inc. (OTCQX: NASB) today announced that its Chief Executive Officer, Thomas B. Wagers, will be retiring from his position of Chief Executive Officer following its annual stockholders meeting in January 2025. Mr. Wagers will remain as a member of the Board of Directors (the "Board") of both NASB Financial, Inc. and its banking subsidiary North American Savings Bank, F.S.B. (collectively, the "Company" or "NASB") following his retirement.

The Company has appointed Enrique Venegas to succeed Mr. Wagers as Chief Executive Officer following Mr. Wagers' retirement, and Mr. Venegas has been named President of both NASB Financial, Inc. and North American Savings Bank, F.S.B. effective October 1, 2024. Mr. Venegas has also been appointed to the Board of both NASB Financial, Inc. and North American Savings Bank, F.S.B. effective October 1, 2024. Prior to his appointment, Mr. Venegas was NASB's Executive Vice-President and Chief Lending Officer. Mr. Venegas was hired as NASB's Chief Credit Officer in 2013 and has over twenty years of banking experience.

"Tom steered NASB through some very difficult and challenging times, including guiding us through the exit from the Consumer Direct business after we decided this was not the right long-term course for our Company," said NASB Chairman David Hancock. "His steadiness, banking acumen and teambuilding focus has positioned us for a bright future. I, as well as all of our managers, have come to rely on him for direction, advice, and encouragement. He is not leaving NASB but has agreed to continue serving on our Board of Directors. His continued counsel will be important as we go forward with the plan he has been instrumental in creating."

"The Board and I are grateful to have someone of Enrique's experience and talent waiting in the wings to assume the CEO role. We believe his leadership, energy and ideas are going to be instrumental in helping the Company achieve its mission."

About NASB
NASB Financial, Inc. is a unitary thrift holding company for North American Savings Bank, F.S.B. Since 1927, NASB has been serving the financial needs of customers by providing an array of personal banking and lending products in the Kansas City metro area. NASB offers competitive residential and commercial mortgages nationwide with the safety and security of a Federal institution. For more information, visit nasb.com.

Forward-Looking Statements
This press release includes "forward-looking statements," which are statements, other than statements of historical facts, regarding our prospects, plans, financial position and business strategy. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we can give no assurance that these expectations will prove to have been correct. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statement. The forward-looking statements included herein are made only as of the date of this press release, and we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

SOURCE NASB Financial, Inc.

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.